Moreover, anti-IL-23 monoclonal antibody acts synergistically with targeted therapies or IL-2 to suppress tumor growth and metastases, supporting the tumor-promoting activity of IL-23 [15]. The gene discussed is IL23A; the disease is neoplasm.